Basilea has reached profitability earlier than expected and has a strong balance sheet and high prospects within its anti-infectives franchise. Our research published today illustrates future opportunities for key drugs, Cresemba and ceftobiprole, together with strategic options for the group.
The early delivery of profitability for Basilea is a laudable achievement. The current anti-infectives franchise is highly profitable, and reducing oncology R&D spending has led to high cash generation. Consequently, Basilea has been able to repay debt and can continue to invest to maintain a strong anti-infectives franchise.
Cresemba is maturing but will continue to grow in the near term, primarily driven by adding new geographies. Ceftobiprole's Phase 3 data should allow US regulatory approval this year, and we expect Basilea to find an appropriate commercial partner. Ceftobiprole promises to be a valuable new treatment for patients with bacteraemia, and we forecast peak sales in the US alone approaching $400m. Basilea has a good track record of partnering assets, and ceftobiprole's potential should allow management to maximise shareholder value through an appropriate agreement. A robust balance sheet coupled with strong cash flows will enable Basilea to in-license relevant candidates and extend the longevity of its anti-infectives business.
We calculate a discounted cash flow fair value of CHF 91 per share for Basilea.
15 Mar 2023
Basilea Pharmaceutica - The future in anti-infectives
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Basilea Pharmaceutica - The future in anti-infectives
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
15 Mar 2023 -
Author:
Brian White | Andrew Keith -
Pages:
19
Basilea has reached profitability earlier than expected and has a strong balance sheet and high prospects within its anti-infectives franchise. Our research published today illustrates future opportunities for key drugs, Cresemba and ceftobiprole, together with strategic options for the group.
The early delivery of profitability for Basilea is a laudable achievement. The current anti-infectives franchise is highly profitable, and reducing oncology R&D spending has led to high cash generation. Consequently, Basilea has been able to repay debt and can continue to invest to maintain a strong anti-infectives franchise.
Cresemba is maturing but will continue to grow in the near term, primarily driven by adding new geographies. Ceftobiprole's Phase 3 data should allow US regulatory approval this year, and we expect Basilea to find an appropriate commercial partner. Ceftobiprole promises to be a valuable new treatment for patients with bacteraemia, and we forecast peak sales in the US alone approaching $400m. Basilea has a good track record of partnering assets, and ceftobiprole's potential should allow management to maximise shareholder value through an appropriate agreement. A robust balance sheet coupled with strong cash flows will enable Basilea to in-license relevant candidates and extend the longevity of its anti-infectives business.
We calculate a discounted cash flow fair value of CHF 91 per share for Basilea.